Draft policy for pricing pharma products prepared

15 Mar, 2013

The National Regulation and Services (NRS), Secretary Imtiaz Inayat Elahi informed that a draft policy was prepared regarding pricing pharmaceutical products. This, he stated while talking to business community during his visit to Sarhad Chamber of Commerce and Industry (SCCI) on the other day.
He said the policy would be shared with the chamber and pharmaceutical industries in Khyber Pakhtunkhwa. He asked the chamber to give a concrete proposals and recommendation in this regard. On the occasion, Inayat also announced to give representation to drug manufacturers association KP into Drug Regulatory Authority board for registration of Pharmaceutical Production, and pricing and licensing.
The NRS, he assured that a special committee would be constituted for registration of pharmaceutical products, which could be helpful for finalisation the registration process rapidly. This, he stated while talking to members of business community during his visit to Sarhad Chamber of Commerce and Industry SCCI on Wednesday. The NRA, Deputy Secretary Mir Rehman, Drug Regulatory Authority Pakistan, Directors Dr Ghulam Rasul, Dr Abdur Rasheed, SCCI president, Dr Yousuf Sarwar, Chairman SCCI standing committee on Pharmaceutical Industry, Riaz Arshad, Pharmaceutical Association KP president, Imtiaz Ahmad, and SCCI vice presidents, Malik Iftikhar Ahmad Awan, Mohammad Anees Ashraf, SCCI executive body members and renowned industrialists and businessmen were present on the occasion.
Imtiaz Inayat informed they are working on pricing policy, for which a draft policy was prepared. He said the policy would be shared with the chamber and pharmaceutical industries in Khyber Pakhtunkhwa. He asked the chamber to give a concrete proposals and recommendation in this regard. While speaking on the occasion, SCCI chief raised the issue of registration process of Pharmaceutical Products, informed that those pharmaceutical units had send samples for registration in 2010, were yet to be registered. He said delay was caused the manufacturing of counterfeit medicine in the local markets.

Read Comments